GenMark Diagnostics Financials

GenMark Diagnostics Stock Summary

GenMark Diagnostics competes with Keurig Dr, Molson Coors, Vita Coco, Ambev SA, and Diageo PLC. GenMark Diagnostics, Inc., a molecular diagnostics company, engages in the developing and commercializing molecular panels based on its proprietary eSensor electrochemical detection technology. The company was incorporated in 2010 and is headquartered in Carlsbad, California. Genmark Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 618 people.

GenMark Diagnostics Key Financial Ratios

Generally speaking, GenMark Diagnostics' financial ratios allow both analysts and investors to convert raw data from GenMark Diagnostics' financial statements into concise, actionable information that can be used to evaluate the performance of GenMark Diagnostics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that GenMark Diagnostics reports annually and quarterly.

GenMark Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining GenMark Diagnostics's current stock value. Our valuation model uses many indicators to compare GenMark Diagnostics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across GenMark Diagnostics competition to find correlations between indicators driving GenMark Diagnostics's intrinsic value. More Info.GenMark Diagnostics is one of the top stocks in return on equity category among related companies. It is one of the top stocks in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value GenMark Diagnostics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for GenMark Diagnostics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the GenMark Diagnostics' earnings, one of the primary drivers of an investment's value.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

If you are still planning to invest in GenMark Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GenMark Diagnostics' history and understand the potential risks before investing.